Na Cocer Peptides bin rayt am 
1 mɔnt dɔn pas
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Fɔ fat dɔn bi wan siriɔs pɔblik wɛlbɔdi prɔblɛm ɔlsay na di wɔl, wit bɔku bad bad tin dɛn we kin apin to pipul dɛn bɔdi, lɛk fɔ mek dɛn gɛt sik dɛn we de mek dɛn at ɛn blɔd, dayabitis, ɛn ɔda tin dɛn we nɔ de mɛn. Insay di las ia, GLP-1 drɔgs dɔn kɔmɔt as prɔmis tritmɛnt opshɔn pan di fild fɔ ɔbisiti mɛnejɛmɛnt.
Figure 1 di poshubul mεkanism dεm fכ weit lכs we GLP-1 kכz. GI, Gastrointestinal we de wok fɔ di bɔdi; GLP-1, Glukagon-layk pεptida-1; GLP-1R, Glucagon-layk pεptida-1 rεsεptכr.
Di Mɛkanism fɔ Akshɔn fɔ GLP-1 Drug dɛn na Ɔbisiti Tritmɛnt
GLP-1 na εndojεnik pεptida we L sεl dεm de sekret insay di intestinal εndokrin sistεm. GLP-1 dכg dεm we dεn kכl bak GLP-1 rεsεptכr agonist (GLP-1 RA dεm), de mεk di fysiolojikal ifekt dεm we GLP-1 de gi bay we dεn de aktibכt di GLP-1 rεsεptכr εn in dכwnstrim signal path dεm, we de mek dεn de εksyεrt difrεn fysiolojikal ifekt dεm we de εp fכ kכntrכl di wet.
fכ mek insulin sekreshכn: GLP-1 RA dεm de mek insulin sekreshכn frכm pankrεas β sεl dεm insay wan we we dipεnd pan glukכs. we di blכd glukכs lεvεl go כp, di GLP-1 RA dεm de biεn di GLP-1 rεsεpכta dεm na di sεf fכ di pankrεas β sεl dεm, we de aktibכt di intasεlulyar signal path dεm fכ promuot insulin sεntesis εn rilis, we de mek di bכdi glukכs lεvεl dכn. fכ stεbyul di blכd glukכs lεvεl de εp fכ ridyus fεt sεntesis εn stכrej, fכ mek di apɛtit inkrεs εn weit gεn we kכz fכ di blכd glukכs fכlt.
di apεtit sכpreshכn: di GLP-1 RA dεm de akt pan di sεntri nεv sεstem, patikyular di bren rijyכn dεm we de asai wit apetit rεguleshכn, lεk di haypothalamus. bay we dεn de biεn di GLP-1 rεsεpכta dεm na di sεf fכ di haypothalamic nyuron dεm, dεn de rεgεl nyuropεptida rilis, lεk fכ ridyus di sekreshכn fכ di pεpti dεm we de mek di apetit εn inkrεs di εksprεshכn fכ di pεpti dεm we de sכpres di apɛtit, we de mek dεn fil fכ ful, dεn de ridyus di it we dεn de it, εn fכ kכntrכl di wet.
dilay di gastric emptying: GLP-1 RA dεm de slo di rεt we di gastric kכntεnt dεm de go insay di sכmכl intestin, i de lכng di tεm we di it de rεst na di bεlε εn i de prodyuz wan sכstayn sεns fכ ful. dis delay gastric emptying nכ de כnli ridyus di it saiz bכt i de stεbyul di bכdi glukכs lεvεl, we de mek di bכdi glukכs spik nכ de afta it εn dat de ridyus di fεt we de kכmכt.
Skim 1 Wan skematik ɔvaviu fɔ GLP-1 rεsεptכr agonist dεm: klasification, drog sefty, εn ifektivεns. GI, Gastrointestinal we de wok fɔ di bɔdi; GLP-1R, Glucagon-layk pεptida-1 rεsεptכr; PEG, Polietilen glykol.
Aplikeshɔn fɔ GLP-1 drɔgs insay ɔbisiti tritmɛnt
Di tritmɛnt fɔ big pipul dɛn we fat: Insay di tritmɛnt fɔ big pipul dɛn we fat, GLP-1 RA dɛn dɔn gɛt impɔtant rizɔlt. Di Faz III klinik trayal fɔ semaglutide dɔn dɔn, wit di rizɔlt dɛn we sho se i gɛt impɔtant weit lɔs ifɛkt. Insay di STEP 2.4 mg/wik semaglutide projɛkt, di pasɛnt dɛn bin gɛt signifyant weit lɔs, we kɔnfyus mɔ di ɛfifikɛshɔn fɔ GLP-1 RA dɛn fɔ di tritmɛnt fɔ big pipul dɛn we fat. Dɛn kin yuz dɛn mɛrɛsin ya as pat pan wan kɔmprɛhnsiv weit lɔs program, we dɛn jɔyn wit it kɔntrol ɛn mɔdaret ɛksɛsayz, fɔ mek dɛn gɛt bɛtɛ wet lɔs autkam.
Tritmɛnt fɔ pikin dɛn we fat pasmak: Stɔdi dɛn we dɛn jɔs dɔn du dɔn sho se dɛn dɔn yuz GLP-1 drɔgs lɛk exenatide, semaglutide, ɛn liraglutide fɔ trit tin dɛn we gɛt fɔ du wit pikin dɛn we fat pasmak, lɛk fɔ fat bad bad wan, fɔ fat pasmak we gɛt fɔ du wit polycystic ovary syndrome (PCOS), ɛn hypothalamic obesity. Fɔ ɛgzampul, stɔdi dɔn sho se dɛn drɔgs ya gɛt sɔm ifɛkt fɔ kɔntrol di wet we pikin dɛn de gɛt, ɛp fɔ mek di mɛtabolik paramita dɛn bɛtɛ, ɛn gi nyu opshɔn fɔ trit di pikin dɛn we fat pasmak.
Fat tritmɛnt fɔ spɛshal pipul dɛm - PCOS pasɛnt dɛm: Polycystic ovary syndrome (PCOS) na kɔmɔn ɛndokrin disɔda pan uman dɛm we dɔn ol fɔ bɔn pikin, ɛn fat pasmak de bɔku pan PCOS pasɛnt dɛm. GLP-1 RA dεm gεt yunik advantej fכ trit fכ fat pan PCOS pasεnshכn dεm. stכdi dεn sho se GLP-1 tεrapi nכ de כnli ridyus di wet pan PCOS pasεnshכn dεm bכt i de impruv insulin rεsistεns, lכs haypa androjenism, εn ivin inkrεs di chans fכ nכmal kכnsepshכn εn in vitro fεtilayzεshכn. Dis de mek GLP-1 RA dɛn bi wan tritmɛnt opshɔn we rili prɔmis fɔ fat PCOS pasɛnt dɛn, we de gi nyu we fɔ mek dɛn wɛlbɔdi ɛn fεtiliti bɛtɛ.
Dɔn
Fɔ sɔmtin, GLP-1 drɔgs, as wan fɔs we de kam ɔp na di fil fɔ tritmɛnt fɔ fat, de sho prɔmis aplikeshɔn prɔspɛkt fɔ trit fat pan big pipul, pikin, ɛn spɛshal pipul dɛn (lɛk PCOS pasɛnt dɛn) bikɔs ɔf dɛn yon we fɔ akshɔn. tru mכltipכl path dεm, we inklud fכ protεkt insulin sekreshכn, sכpres apεtit, εn delay gastric εmpti, GLP-1 RA dεm de εp di sikman dεm fayn fayn wan fכ ridyus di wet εn impruv mεtabolik stetכs.
Insay di tritmɛnt fɔ big pipul dɛn we fat, dɛn dɔn validet drɔgs lɛk liraglutide ɛn semaglutide tru klinik trial, we de gi tritmɛnt opshɔn dɛn we pɔsin kin abop pan fɔ di wan dɛn we fat. Insay di tritmɛnt fɔ fat pan PCOS pasɛnt dɛn, GLP-1 RA dɛn nɔ jɔs de ɛp fɔ ridyus di wet bɔt dɛn de ɛp bak fɔ impɔtant di ɛndɔkrin dizayd dɛn we gɛt fɔ du wit di kɔndishɔn, we de gi bɔku bɛnifit to PCOS pasɛnt dɛn.
Sos dɛn we dɛn pul
[1] Zhang D, Lu H. GLP-1RA: Nyu Op in Ɔbisiti Tɛrapi[J]. J ɔ rnal ov Bayosayns ɛn Mɛdisin, 2025,13(2):465-479. https://cstj.cqvip.com/Qikan/Atikul/Ditayl?id=HS727602025002035. Di wan dɛn we de stɔdi bɔt di Baybul
[2] Kavarian PN, Mosher TL, Haija MA E. Yuz glukagon-layk-pεptida 1 rεsεptכr agonist in di tritmεnt fכ pikin fכ fat.[J]. Kɔrɛnt Opinion in Pidiatrik, 2024,36 5:542-546. https://api.semanticscholar.org/CorpusID:272115519. Di wan dɛn we de stɔdi bɔt di Baybul
[3] Wang JY, Wang QW, Yang XY, ɛn ɔda pipul dɛn. GLP-1 rεsεptכr agonist dεm fכ di tritmεnt fכ fat: Rol as prכmis aprכch[J]. Frɔntiers in Ɛndokrinɔlɔji, 2023,14:1085799.DOI:10.3389/fendo.2023.1085799.
[4] Pedrosa M. R., Franko D. R., Gieremek H. W., ɛn ɔda pipul dɛn. GLP-1 Agonist fכ Trit Obesity εn Prεvεnt Cardiovascular Disease: Wetin Wi Dɔn Achiv so Fa?[J]. Kɔrɛnt Atɛrosklɛrosis Ripɔt, 2022,24(11):867-884.DOI:10.1007/s11883-022-01062-2.
[5] Baranowska-Bik A. Tεrapi fכ fat pan uman dεm we gεt PCOS we de yuz GLP-1 analכg - bεnεfit εn limitεshכn [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 - korzyści i ograniczenia][J]. Ɛndokrinɔlɔjia Polska, 2022,73(3):627-643.DOI:10.5603/EP.a2022.0047.
